anti vegf drug Search Results


anti-vegf drug pegaptanib macugen  (OSI Pharmaceuticals)
90
OSI Pharmaceuticals anti-vegf drug pegaptanib macugen
Hypothetical vs. actual drug and delivery expenditures <t>on</t> <t>anti-VEGF</t> therapy for <t>nvAMD,</t> 2008 – 2015. Fixed-regimen spending is shown in black, personalized-regimen spending is depicted with a cross-hatch pattern and actual spending is shown in a striped pattern. Aflibercept spending is limited to 2013 – 2015.
Anti Vegf Drug Pegaptanib Macugen, supplied by OSI Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-vegf drug pegaptanib macugen/product/OSI Pharmaceuticals
Average 90 stars, based on 1 article reviews
anti-vegf drug pegaptanib macugen - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-vegf drug for macular degeneration  (Eyetech Inc)
90
Eyetech Inc anti-vegf drug for macular degeneration
Hypothetical vs. actual drug and delivery expenditures <t>on</t> <t>anti-VEGF</t> therapy for <t>nvAMD,</t> 2008 – 2015. Fixed-regimen spending is shown in black, personalized-regimen spending is depicted with a cross-hatch pattern and actual spending is shown in a striped pattern. Aflibercept spending is limited to 2013 – 2015.
Anti Vegf Drug For Macular Degeneration, supplied by Eyetech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-vegf drug for macular degeneration/product/Eyetech Inc
Average 90 stars, based on 1 article reviews
anti-vegf drug for macular degeneration - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
oral anti-vascular endothelial growth factor (vegf) drug pazopanib votrient  (Glaxo Smith)
90
Glaxo Smith oral anti-vascular endothelial growth factor (vegf) drug pazopanib votrient
Hypothetical vs. actual drug and delivery expenditures <t>on</t> <t>anti-VEGF</t> therapy for <t>nvAMD,</t> 2008 – 2015. Fixed-regimen spending is shown in black, personalized-regimen spending is depicted with a cross-hatch pattern and actual spending is shown in a striped pattern. Aflibercept spending is limited to 2013 – 2015.
Oral Anti Vascular Endothelial Growth Factor (Vegf) Drug Pazopanib Votrient, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oral anti-vascular endothelial growth factor (vegf) drug pazopanib votrient/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
oral anti-vascular endothelial growth factor (vegf) drug pazopanib votrient - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Hypothetical vs. actual drug and delivery expenditures on anti-VEGF therapy for nvAMD, 2008 – 2015. Fixed-regimen spending is shown in black, personalized-regimen spending is depicted with a cross-hatch pattern and actual spending is shown in a striped pattern. Aflibercept spending is limited to 2013 – 2015.

Journal: American journal of ophthalmology

Article Title: Estimating public and patient savings from basic research - a study of optical coherence tomography in managing anti-angiogenic therapy

doi: 10.1016/j.ajo.2017.09.027

Figure Lengend Snippet: Hypothetical vs. actual drug and delivery expenditures on anti-VEGF therapy for nvAMD, 2008 – 2015. Fixed-regimen spending is shown in black, personalized-regimen spending is depicted with a cross-hatch pattern and actual spending is shown in a striped pattern. Aflibercept spending is limited to 2013 – 2015.

Article Snippet: For example, the first, now rarely used, anti-VEGF drug to treat nvAMD known as pegaptanib (Macugen, OSI Pharmaceuticals, Melville, NY) required one injection every six weeks.

Techniques:

Government investment in OCT vs. savings from OCT-guided anti-VEGF therapy for nvAMD. Medicare savings is from 2008 – 2015 due to reduced drug and delivery costs. Medicare spending on reimbursing clinicians for OCT imaging is from 2008 – 2015, while research spending on OCT by the NIH and NSF is from 1995 – 2015.

Journal: American journal of ophthalmology

Article Title: Estimating public and patient savings from basic research - a study of optical coherence tomography in managing anti-angiogenic therapy

doi: 10.1016/j.ajo.2017.09.027

Figure Lengend Snippet: Government investment in OCT vs. savings from OCT-guided anti-VEGF therapy for nvAMD. Medicare savings is from 2008 – 2015 due to reduced drug and delivery costs. Medicare spending on reimbursing clinicians for OCT imaging is from 2008 – 2015, while research spending on OCT by the NIH and NSF is from 1995 – 2015.

Article Snippet: For example, the first, now rarely used, anti-VEGF drug to treat nvAMD known as pegaptanib (Macugen, OSI Pharmaceuticals, Melville, NY) required one injection every six weeks.

Techniques: Imaging